Monitoring HIV Medication Intake with a Smart System
Unobtrusive Sensing of Medication Intake ("USE-MI")
This study is testing a smartwatch and app system to help people with HIV remember to take their medications on time and see if it makes sticking to their treatment easier.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Swedish Medical Center Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Trial ID | NCT03571022 on ClinicalTrials.gov |
What this trial studies
This study evaluates the USE-MI system, which utilizes a smartwatch and smartphone app to monitor and enhance medication adherence among individuals taking HIV-related medications. The system aims to provide real-time tracking of medication intake and send electronic reminders to participants who may forget to take their medications. Initially, 10 subjects will test the system for one month, followed by a larger group of up to 50 subjects over six months to assess the system's accuracy, robustness, and acceptability. The goal is to improve adherence to antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) for better health outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals with HIV who are on ART or those at risk of HIV infection who are taking PrEP and can manage their own medication.
Not a fit: Patients who are not responsible for their own medication intake, such as those in supervised settings, will not benefit from this study.
Why it matters
Potential benefit: If successful, this system could significantly improve medication adherence for patients with HIV, leading to better health outcomes and reduced transmission rates.
How similar studies have performed: Other studies have shown promise in using technology to enhance medication adherence, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Either a) have an HIV infection and are taking ART, or b) risk factors for contracting HIV infection and are taking PrEP * Taking their medications from pill bottles, or other containers that the USE-MI system can monitor properly * Reasonable proficiency in English * Able to come to the research office for monthly follow-up visits Exclusion Criteria: * Not responsible for taking their own HIV medications (e.g. residing in a supervised setting where their medications are administered to them) * Taking medications using a method that the USE-MI system cannot monitor properly * Lacking proficiency in English
Where this trial is running
Seattle, Washington
- Swedish Medical Center — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Barry Saver, MD — Swedish Medical Center
- Study coordinator: Jacob Karr
- Email: jacob.karr@swedish.org
- Phone: 206-215-4226
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.